EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myeloma

Access, MyelomaLeave a comment

The European Medicines Agency (EMA) has recommended a conditional marketing authorisation in the European Union (EU) for teclistamab for the treatment of adult patients with relapsed and refractory myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment. Teclistamab, alternatively known under the branded name Tecvayli, is a monoclonal antibody that targets two proteins at the same time: a protein called…